Pro­to­cols: In­fin­i­ty hunts up a buy­er for its dis­ap­point­ing can­cer drug du­velis­ib; Is North­west Bio fi­nal­ly broke?

Ab­b­Vie’s de­ci­sion to abrupt­ly pull out of its part­ner­ship with In­fin­i­ty on du­velis­ib large­ly wrecked the com­pa­ny’s hopes to fi­nal­ly make it big af­ter re­peat­ed set­backs over the years. But In­fin­i­ty CEO Ade­lene Perkins isn’t giv­ing up. She tells BioWorld that the com­pa­ny is push­ing ahead in search of an ac­cel­er­at­ed ap­proval – the drug hit its end­point but looked com­mer­cial­ly fee­ble – while scout­ing for an­oth­er com­pa­ny will­ing to buy it. “We have sev­er­al par­ties who are in­ter­est­ed [in du­velis­ib] and we’re in dis­cus­sions,” Perkins told the news group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER